EG 002
Alternative Names: EG-002Latest Information Update: 11 Apr 2022
At a glance
- Originator Evergreen Therapeutics
- Class Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Nephrotic syndrome
Most Recent Events
- 11 Apr 2022 EG 002 receives Orphan Drug status for Nephrotic syndrome in China (Evergreen Therapeutics pipeline, April 2022)
- 23 Oct 2020 Preclinical trials in Nephrotic syndrome (In children) in China (PO) (Shenzhen Eglin Pharmaceutical pipeline, October 2020)
- 03 Mar 2020 Shenzhen Evergreen Therapeutics has patent protection for the use of progestogen as a glucocorticoid sensitizer methods in US, Japan, Europe and China